Effect of counterions on physicochemical properties of prazosin salts

AAPS PharmSciTech

Volumn 14, Issue 1, 2013, Pages 141-150

  Kumar, Lokesh ^a   Meena, Chhuttan Lal ^a   Pawar, Yogesh B ^a   Wahlang, Banrida ^a   Tikoo, Kulbhushan ^a   Jain, Rahul ^a   Bansal, Arvind K ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

prazosin; preformulation; salt form; salt screening

Indexed keywords

COUNTERION; PRAZOSIN;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN CACO 2; DRUG BIOAVAILABILITY; DRUG MARKETING; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; HUMIDITY; HYDRATION; HYDROPHILICITY; IN VIVO STUDY; MALE; MELTING POINT; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SOLID STATE; WETTABILITY;

ADRENERGIC ALPHA-ANTAGONISTS; CACO-2 CELLS; CALORIMETRY, DIFFERENTIAL SCANNING; CHROMATOGRAPHY, GAS; HUMANS; MASS SPECTROMETRY; PRAZOSIN; SALTS; SOLUBILITY; THERMOGRAVIMETRY;

EID: 84878575159     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9889-x     Document Type: Article

References (32)

1. Berge SM, Bighley LM, Monkhouse DC. Pharmaceutical salts. J Pharm Sci. 1977;66:1-19.
2. Black SN, Collier EA, Davey RJ, Roberts RJ. Structure, solubility, screening, and synthesis of molecular salts. J Pharm Sci. 2007;96:1053-68.
3. Bowker MJ. A procedure for salt selection and optimization. In: Stahl PH, Wermuth CG, editors. Handbook of pharmaceutical salts: properties, selection and use. Weinheim: Wiley-VCH Inc.; 2002. p. 161-89.
4. Davies G. Changing the salt, changing the drug. Pharm J. 2001;266:322-3.
5. Gould PL. Salt selection for basic drugs. Int J Pharm. 1986;33:201-17.
6. Serajuddin ATM. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007;59:603-16.
7. Stahl PH, Nakano M. Pharmaceutical aspects of the drug salt form. In: Stahl PH, Wermuth CG, editors. Handbook of pharmaceutical salts: properties, selection and use. Weinheim: Wiley-VCH Inc.; 2002. p. 83-116.
8. Kumar L, Amin A, Bansal AK. Preparation and characterization of salt forms of enalapril. Pharm Dev Technol. 2008;13:345-57.
9. Morris KR, Fakes MG, Thakur AB, Newman AW, Singh AK, Venit JJ, et al. An integrated approach to the selection of optimal salt form for a new drug candidate. Int J Pharm. 1994;105:209-17.
10. Gilman AG, Goodman LS, Gilman A. Goodman and Gilman's the pharmacological basis of therapeutics. 6th ed. New York: McMillan; 1980. p. 806-7.
11. Hofmann BB. Adrenergic receptor blocking agents. In: Katzung BG, editor. Basic and clinical pharmacology. Los Altos: Lange Medical; 1984. p. 97-107.
12. Wu S. Polar and nonpolar interactions in adhesion. J Adhes. 1973;5:39-55.
13. Bianco EJ. Novel crystalline forms of prazosin hydrochloride. US Patent 4092315; 1978.
14. Kostek LJ. Prazosin hydrochloride. In: Brittain HG, editor. Analytical profile of drug substances and excipients, vol. 18. Amsterdam: Elsevier; 1989. p. 351-81.
15. Bergström CAS, Norinder U, Luthman K, Artursson P. Experimental and computational screening models for prediction of aqueous drug solubility. Pharm Res. 2002;19:182-8.
16. Kostek LJ. Prazosin hydrochloride. Analytical Profile of Drug Substances and Excipients. 1989;18:351-81.
17. Prazosin permeability. http://www.cyprotex.com/cloescreen/in-vitro- permeability/mdr1-mdck-permeability/. Accessed 1 May 2012.
18. Bianco EJ. Novel crystalline forms of prazosin hydrochloride. US Patent 4092315, Pfizer Inc.; 1978.
19. Kumar L, Bansal AK. Effect of humidity on the hydration behaviour of prazosin hydrochloride polyhydrate: thermal, sorption and crystallographic study. Thermochim Acta. 2012;525:206-10.
20. a determination of water-insoluble compounds: validation study in a new cosolvent system. Anal Chim Acta. 2007;583:418-28.
21. Tong W. Salt screening and selection: new challenges and considerations in the modern pharmaceutical R&D paradigm. http://www.pharmacy.utah.edu/ pharmaceutics/pdf/Salt.pdf. Accessed 5 May 2012.
22. MDR1-MDCK permeability (P-glycoprotein substrate identification). http://www.cyprotex.com/cloescreen/in-vitro-permeability/mdr1-mdck-permeability/ . Accessed 1 May 2012.
23. Bogardus JB. Common ion equilibria of hydrochloride salts and the Setschenow equation. J Pharm Sci. 1982;71:588-90.
24. Engel GL, Farid NA, Faul MM, Richardson LA, Winneroski LL. Salt form selection and characterization of LY333531 mesylate monohydrate. Int J Pharm. 2000;198:239-47.
25. Miyazaki S, Oshiba M, Nadai T. Precaution on use of hydrochloride salts in pharmaceutical formulation. J Pharm Sci. 1981;70:594-6.
26. Bowker MJ, Stahl PH. Preparation of water-soluble compounds through salt formation. In: Wermuth CG, editor. The practice of medicinal chemistry. London: Academic; 2008. p. 749-66.
27. Agharkar S, Lindenbaum S, Higuchi T. Enhancement of solubility of drug salts by hydrophilic counterions: properties of organic salts of an antimalarial drug. J Pharm Sci. 1976;65:747-9.
28. Gu L, Strickley RL. Preformulation salt selection - physical property comparison of the tris(hydroxymethyl)aminomethane salts of four analgesic/antiinflammatory agents with the sodium salts and the free acids. Pharm Res. 1987;4:255-7.
29. Anderson BD, Conradi RA. Predictive relationships in the water solubility of salts of a nonsteroidal anti-inflammatory drug. J Pharm Sci. 1985;74:815-20.
30. Chowhan JT. pH-solubility profiles of organic carboxylic acids and their salts. J Pharm Sci. 1978;67:1257-60.
31. Guerrieri P, Rumondor ACF, Li T, Taylor LS. Analysis of relationships between solid-state properties, counterion, and developability of pharmaceutical salts. AAPS PharmSciTech. 2010;11:1212-22.
32. Rubino JT. Solubility and solid state properties of the sodium salts of drugs. J Pharm Sci. 1989;78:485-9.